研究業績

2019年 研究業績

1. Niimi N, Takaku S, Yako H, Sango K. Chapter 23: Drug-induced demyelinating neuropathies. In: Myelin-Basic and Clinical Advances-, Advances in Experimental Medicine and Biology, Vol.1190 (Sango K, Yamauchi J, Ogata T, Susuki K, eds.), Springer, Singapore, pp.357-369 (2019)
2. Makino E, Nakamura N, Miyabe M, Ito M, Kanada S, Hata M, Saiki T, Sango K, Kamiya H, Nakamura J, Miyazawa K, Goto S, Matsubara T, Naruse K. Conditioned media from dental pulp stem cells improved diabetic polyneuropathy via anti-inflammatory, neuroprotective and angiogenic actions: cell-free regenerative medicine for diabetic polyneuropathy. J Diabetes Investig 10, 1199-1208 (2019)
3. Kato A, Tatsumi Y, Yako H, Sango K, Himeno T, Kondo M, Kato Y, Kamiya H, Nakmura J, Kato K. Recurrent short-term hypoglycemia and hyperglycemia induce apoptosis and oxidative stress via the ER stress response in immortalized adult mouse Schwann (IMS32) cells. Neurosci Res 147, 26-32 (2019)
4. Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu Y, Kim DK, Jung BC, Choi M, Oh KW, Li Y, Nakatani M, Nakazato T, Sekimoto S, Funayama M, Yoshino H, Kubo SI, Nishioka K, Sakai R, Ueyama M, Mochizuki H, Lee HJ, Sardi SP, Halliday GM, Nagai Y, Lee PH, Hattori N, Lee SJ. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Brain 142, 2845-2859 (2019)
5. Ikenaka K, Suzuki M, Mochizuki H, Nagai Y. Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson's Disease. Front Neurosci, 13, 693 (2019)
6. Sakai R, Suzuki M, Ueyama M, Takeuchi T, Minakawa EN, Hayakawa H, Baba K, Mochizuki H, Nagai Y. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease. PLoS One, 14, e0218261 (2019)
7. Tatsumi Y, Kato A, Mano M, Sango K, Himeno T, Kondo M, Kato Y, Kamiya H, Nakamura J, Kato K. Omega-3 polyunsaturated fatty acids exert antioxidant effects through the Nrf2 pathway in the immortalized mouse Schwann IMS32 Cells. J Diabetes Invest, 10, 602-612 (2019)
8. Nakamura S*, Oba M*, Suzuki M, Takahashi A, Yamamuro T, Fujiwara M, Ikenaka K, Minami S, Tabata N, Yamamoto K, Kubo S, Tokumura A, Akamatsu K, Miyazaki Y, Kawabata T, Hamasaki M, Fukui K, Sango K, Watanabe Y, Takabatake Y, Kitajima TS, Okada Y, Mochizuki H, Isaka Y, Antebi A, Yoshimori T. Suppression of autophagic activity by Rubicon is a signature of aging. Nat Commun, 10:847 (2019) (*First authors)
9. Tatsumi Y, Matsumoto N, Iibe N, Watanabe N, Torii T, Sango K, Homma K, Miyamoto Y, Sakaguchi H, Yamauchi J. CMT type 2N disease-associated AARS mutant inhibits neurite outgrowth that can be reversed by valproic acid. Neurosci Res, 139:69-78 (2019)
10. Niimi N, Yako H, Takaku S, Sango K. Chapter 2: Pathogenetic mechanisms of amiodarone-induced peripheral neuropathy. In: Advances in Medicine and Biology, Vol.136 (Ed:Berhardt LV), Nova Science Publishers, Inc, Hauppauge, USA, pp.41-62 (2019).